HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

SkinMedica is acquired by BOTOX and Latisse maker Allergan for $350 million. NAD says BIC USA can support claims that its razors feature “flexible blades” following a challenge by Schick marketer Energizer Personal Care.

You may also be interested in...



New Products In Brief: Bee Bald Adds To Line; AXE For Women; More

Bee Bald Shave and Bee Bald Scrub debut from brand focused on the “follically challenged,” while AXE caters to its female fans with new shower gels for women. More new products in brief.

SkinMedica Expands Into Mineral Makeup With Addition of Colorescience

Carlsbad, Calif-based SkinMedica seeks to capitalize on projected growth in the professional skin-care sector with the addition of Colorescience. The acquisition adds mineral makeup to SkinMedica’s portfolio of prescription and non-prescription skin-care products sold through doctors’ offices.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel